Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.

@article{Trujillo2014AlbiglutideAN,
  title={Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.},
  author={Jennifer M Trujillo and Wesley Nuffer},
  journal={The Annals of pharmacotherapy},
  year={2014},
  volume={48 11},
  pages={
          1494-501
        }
}
OBJECTIVE To review the pharmacology, pharmacokinetics, safety, and efficacy of albiglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) in type 2 diabetes (T2D). DATA SOURCES A MEDLINE search (1950-June 2014) was conducted using the keyword albiglutide. References were reviewed to identify additional sources. STUDY SELECTION AND DATA EXTRACTION Articles evaluating pharmacokinetics, pharmacodynamics, safety, or efficacy of albiglutide were included. DATA SYNTHESIS Albiglutide is… CONTINUE READING
BETA
5
Twitter Mentions

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 16 CITATIONS

Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide

VIEW 19 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Targeting the gastrointestinal tract to treat type 2 diabetes.

  • The Journal of endocrinology
  • 2016
VIEW 16 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Controlled release of biologics for the treatment of type 2 diabetes.

  • Journal of controlled release : official journal of the Controlled Release Society
  • 2016